Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis
- 14 April 2008
- journal article
- clinical trial
- Published by Elsevier BV in Surgery
- Vol. 143 (6), 759-768
- https://doi.org/10.1016/j.surg.2008.02.007
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Development and validation of pheochromocytoma of the adrenal gland scaled score for predicting malignant pheochromocytomasUrology, 2006
- Gene Expression Profiling of Benign and Malignant PheochromocytomaAnnals of the New York Academy of Sciences, 2006
- Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosisCancer, 2006
- Expression of chromogranins A, B, and C (secretogranin II) in human adrenal medulla and in benign and malignant pheochromocytomas An immunohistochemical study with region-specific antibodiesAPMIS, 2004
- CGH and CD 44/MIB-1 immunohistochemistry are helpful to distinguish metastasized from nonmetastasized sporadic pheochromocytomasLaboratory Investigation, 2004
- KI-67 AND hTERT Expression Can Aid in the Distinction between Malignant and Benign Pheochromocytoma and ParagangliomaLaboratory Investigation, 2003
- Characterization of Gene Expression Induced by RET with MEN2A or MEN2B MutationThe American Journal of Pathology, 2002
- Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) to Separate Benign From Malignant NeoplasmsThe American Journal of Surgical Pathology, 2002
- Adrenocortical Carcinoma: Clinical, Morphologic, and Molecular CharacterizationJournal of Clinical Oncology, 2002
- Prognostic Value of Immunohistochemical Expression of Topoisomerase Alpha II, MIB-1, p53, E-Cadherin, Retinoblastoma Gene Protein Product, and HER-2/neu in Adrenal and Extra-adrenal PheochromocytomasApplied Immunohistochemistry & Molecular Morphology, 2000